Evofem Biosciences To Present At The H.C. Wainwright BIOCONNECT 2021 Virtual Conference

SAN DIEGO, Dec. 21, 2020 /PRNewswire/ -- Evofem Biosciences, Inc.
Author:
Publish date:

SAN DIEGO, Dec. 21, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) - Get Report today announced it will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.

Evofem's CEO, Saundra  Pelletier, will provide updates on the commercialization of Phexxi® (lactic acid, citric acid and potassium bitartrate) , the first and only FDA-approved, hormone free contraceptive vaginal gel, and the pivotal Phase 3 EVOGUARD  trial, which is evaluating EVO100 for the prevention of chlamydia and gonorrhea in women and currently enrolling subjects at study centers across the U.S. 

The presentation will be available for on-demand listening  beginning Monday, January 11, 2021, at 6:00 AM Eastern Time on the Investors section of the Evofem Biosciences website at  www.evofem.com , under the  Events and Presentations  tab.

About Evofem BiosciencesEvofem Biosciences, Inc., (EVFM) - Get Report is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate) , is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, ' EVOGUARD ,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. For more information, please visit  www.evofem.com .

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact Amy RaskopfEvofem Biosciences, Inc. araskopf@evofem.com Mobile: (917) 673-5775

Media Contact Ellen ThomasEvofem Biosciences, Inc. ethomas@evofem.comMobile: (718) 490-3248

View original content to download multimedia: http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-the-hc-wainwright-bioconnect-2021-virtual-conference-301196515.html

SOURCE Evofem Biosciences, Inc.